expected within one week. The recommended dose of BMZ is 12 mg given intramuscularly twice, each dose 24 hours apart, without regard to maternal body mass index (BMI). Our objective was to determine if maternal prepregnancy weight is a risk factor for neonatal respiratory morbidity and to determine if increasing BMI decreased the efficacy of BMZ. STUDY DESIGN: This was a secondary analysis of the Antenatal Late Preterm Steroids (ALPS) trial, a multicenter, double-blind, randomized controlled trial involving 2,831 women between 34 0/7 weeks and 36 6/7 weeks who were randomized to BMZ or a matching placebo (Gyamfi-Bannerman, N Engl J Med 2016). The primary outcome was the rate of composite neonatal respiratory morbidity within the first 72 hours of life that included continuous positive airway pressure or high flow nasal cannula for 2 hours, oxygen requirement with FiO2 of 30% for 4 hours, any mechanical ventilation or perinatal death. We compared the rate of neonatal respiratory morbidity among prepregnancy BMI classes in both the placebo and treatment groups. We also stratified the treatment effect by maternal BMI at the time of delivery. RESULTS: A total of 2,822 women were identified with maternal weight recorded at delivery. 2,740 women also had self-reported prepregnancy weight available. When stratified by prepregnancy BMI class, there was no significant differences in neonatal respiratory morbidity in the BMZ or in placebo groups (Table 1) . When analyzed by BMI at delivery, there was no significant difference in the rate of neonatal respiratory morbidity ( OBJECTIVE: Current guidelines recommend serial cervical length (CL) monitoring up to 24 weeks' gestation in women with a prior preterm birth (PTB) to assess for candidacy for ultrasound-indicated cerclage placement. The utility of CL monitoring beyond 24 weeks is debatable, but one potential role of this practice could be to inform timing of betamethasone (BMZ) administration. This study sought to evaluate the patterns of BMZ exposure in an at-risk population with shortened cervical length.
STUDY DESIGN:
Retrospective cohort study of all women with a prior spontaneous PTB who underwent serial CL measurements and progesterone prophylaxis at a large academic tertiary medical center from 2011-2016. Women were grouped by shortest recorded CL (<25mm or 25mm). The primary outcome was initial BMZ administration <34 weeks' gestation. Secondary outcomes included rates of rescue BMZ administration, optimal BMZ exposure (latency to delivery 7) and exposure with term delivery. A secondary analysis was performed by specific indication for BMZ as either: 1) short cervix (<25mm) alone, or 2) clinical symptoms concerning for preterm labor. Poisson regression with robust error variance was used to calculate incidence rate ratios (IRR) for the primary and secondary outcomes adjusting for black race, earliest prior PTB, and current cerclage. RESULTS: There were 829 women who met inclusion criteria over the study period, with 358 (43.3%) and 471 (56.7%) in the <25mm and 25mm shortest CL groups, respectively. Exposure to both an initial and rescue BMZ course were more common in the short cervix group (Table 1) . Although, women with short cervix were more likely to delivery preterm (45.8% vs. 28.3%; p<.01), there was no difference in exposure with term delivery. Overall rates of optimal BMZ exposure were low, but less likely in the short cervix group (7.4% vs. 15.7%; p¼.03). There were significant differences in latency of exposure to delivery by indication for BMZ; Figure 1 . Lastly, women with BMZ exposure for asymptomatic short CL were less likely to have optimal steroid exposure before delivery (1.2% vs. 19.0%; p<.01) and more likely to deliver at term (54.2% vs. 36.4%; p<.01) when compared to women given BMZ for symptoms. CONCLUSION: Women with prior PTB and short CL are more likely to receive both an initial and rescue course of BMZ, but are less likely to have optimal exposure. This study challenges the practice of administering BMZ to women with an asymptomatic short cervix.
ajog.org
Poster Session II Supplement to JANUARY 2019 American Journal of Obstetrics & Gynecology S307
